...A. Highlights: Another strong qtr., serving community with three approved therapies: 1. EXONDYS 51. a. b. VYONDYS 53. c. AMONDYS 45. 2. About $5m anticipated for 3Q22 came in and was booked in 2Q22. Even with that: a. i. Total revenue, approx. $230.3m. ii. Net product revenue, $207.8m; 25% growth YoverY. 3. In 2Q22, raised 2022 guidance: a. Total revenue to $905-920m. b. Net product revenue guidance to $825-840m. c. In light of continuing strong performance, remains comfortable with that guidance. B. SRP-9001: SPR-9001 is gene therapy for Duchenne muscular dystrophy. 1. 2. 2022 has been momentous one for SRP-9001 and for Duchenne community Co. serves. 3. Over course of 1H22, Co. discussed with FDA possibility of submitting Biologics License Application (BLA) for approval of SRP-9001 on accelerated basis. Due to those discussions and written feedback Co. received, it intended to submit BLA for approval of SRP-9001 to treat ambulatory Duchenne patients. a. b. In 3Q22, submitted BLA for SRP-9001....